2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5065 Interim analysis of a single-arm, open-label trial combining olverembatinib, CD3/CD19 bispecific T-cell engager, and chidamide for newly diagnosed Ph⁺ ALL (ABC Regimen)

Cai Zihong, Zhixiang Wang2, Wenhao Zhong3, Bailin He4, Xuan Zhou, PhD5, Xiaoli Liu, MD6, Qifa Liu, MD7, Hongsheng Zhou8
1 Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
8 Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People's Hospital), Ganzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China

Background

Chemotherapy-free regimens that combine tyrosine kinase inhibitors (TKIs) with blinatumomab have become a prevailing therapeutic strategy for Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph? B-ALL). The third-generation TKI, Olverembatinib, has demonstrated impressive efficacy in patients with relapsed/refractory (R/R) B-ALL. However, substantial clinical data supporting its frontline therapeutic efficacy are still unavailable. Our preliminary studies demonstrated that chidamide conferred therapeutic benefits for IKZF1DEL B-ALL. (ASH, 2021) In this study, we aimed to evaluate this chemotherapy-free strategy with these three agents when employed as frontline treatment for Ph? B-ALL.

Method

We did a single-centre, single-arm, open-label study at the Nanfang hospital, Guangzhou, China, in patients aged 18 years or older with newly diagnosed Ph-positive acute lymphoblastic leukemia. Patients with an ECOG performance status of 1 or less, normal cardiac function, negative HIV status, adequate hepatic and renal function (ALT/AST ≤ 2×ULN, total bilirubin ≤1.5×ULN, creatinine clearance >50 mL/min), and normal pancreatic function (serum amylase and lipase ≤1.5×ULN) were eligible for inclusion.

A single pretreatment cycle with oral prednisone 1 mg/kg/day on days 1–14 was followed by induction: Olverembatinib 40 mg orally once daily on days 8–42, continuous intravenous blinatumomab 28 μg per day on days 15–28, and chidamide 10 mg orally once daily on days 9–41 was administered in combination during induction, followed by five identical 42-day consolidation cycles. Patients received 12 doses of intrathecal chemotherapy as CNS prophylaxis. The primary endpoints were complete molecular response (defined as absence of a detectable BCR–ABL1 transcript by PCR at a sensitivity of 0·01%). All assessments were done according to the intention-to-treat principle. The trial is registered with ClinicalTrials.gov, NCT06220487, and it is ongoing.

Result

Between October 2023 to now, 34 patients with newly diagnosed Ph+ ALL were enrolled, with a median age of 49 years (range, 18-76). The median follow-up for the entire cohort was 628 days (95% CI 538-717 days). One-third of patients underwent olverembatinib dose de-escalation from 40 mg to 30 mg within 1 year. BCR-ABL1 p190 transcripts were present in 76% (26/34) of patients, and IKZF1 deletion was identified in 12 patients. Complete remission was achieved in all evaluable patients (100%), among whom 32 cases (94%) reached complete molecular response. The most common grade 3–4 adverse events that occurred in more than 5% of patients were infection (9 [26%] patients), hepatic dysfunction (2 [6%] patients), Cerebrovascular adverse events (2 [6%] patients), gastrointestinal adverse events (2 [6%] patients). Only one case of immune effector cell-associated neurotoxicity syndrome (ICANS) was graded as grade 4, leading to discontinuation of blinatumomab therapy. No treatment-related deaths were observed.

Within the entire cohort, the 1-year EFS was 93.6% and 1-year OS was 93.3%. During follow-up, extramedullary relapse occurred in two cases (central nervous system and mammary gland), while intramedullary relapse was observed in one case. Furthermore, no statistically significant differences in EFS and OS were observed between patients with IKZF1 deletion and those with wild-type (WT) IKZF1 (EFS, P=0.505; OS, P=0.212).

Conclusion

This study provides the first clinical evidence supporting the combination of olverembatinib, blinatumomab, and chidamide as a promising frontline therapy for newly diagnosed Ph? B-ALL, warranting further expanded clinical research.

Cai Zihong: No relevant conflicts of interest to declare.